NCT05459870 is a Phase 1, PHASE2 clinical trial of 4SCAR T cells in Autoimmune Diseases, sponsored by Shenzhen Geno-Immune Medical Institute.

Who is sponsoring NCT05459870?

NCT05459870 is sponsored by Shenzhen Geno-Immune Medical Institute.

What drugs are being tested in NCT05459870?

Interventions in NCT05459870: 4SCAR T cells.

What condition does NCT05459870 study?

NCT05459870 studies Autoimmune Diseases.

Is NCT05459870 still recruiting?

NCT05459870 is currently recruiting now. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT05459870

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAR-T Cells Targeting Autoimmune Diseases

Recruiting now Phase 1, PHASE2 Last updated 19 July 2022

What this trial tests

Phase 1, PHASE2 trial testing 4SCAR T cells in Autoimmune Diseases in 30 participants. Currently enrolling.

Timeline

31 July 2022

Primary endpoint
31 July 2025

30 June 2026

Quick facts

Lead sponsor	Shenzhen Geno-Immune Medical Institute
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	31 July 2022
Primary completion	31 July 2025
Estimated completion	30 June 2026
Sites	2 locations across China

Drugs / interventions tested

4SCAR T cells — full drug profile →

Conditions studied

Autoimmune Diseases — all drugs for Autoimmune Diseases →

Sponsor

Shenzhen Geno-Immune Medical Institute

Who can join

Adults 18 to 75, any sex, with Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the feasibility, safety and efficacy of CAR-T cell therapy in patients with autoimmune disease. Another goal of the study is to learn more about the safety and function of the CAR-T cells and their persistency in autoimmune disease patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Chimeric antigen receptor T cell therapy for autoimmune disease.
Chung JB, Brudno JN, Borie D, Kochenderfer JN. · · 2024 · cited 85× · PMID 38831163 · DOI 10.1038/s41577-024-01035-3
CAR T cells for treating autoimmune diseases.
Blache U, Tretbar S, Koehl U, Mougiakakos D, et al · · 2023 · cited 54× · PMID 37996128 · DOI 10.1136/rmdopen-2022-002907
B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
Zhang Z, Xu Q, Huang L. · · 2023 · cited 37× · PMID 36855629 · DOI 10.3389/fimmu.2023.1126421
Cutting-edge approaches to B-cell depletion in autoimmune diseases.
Robinson WH, Fiorentino D, Chung L, Moreland LW, et al · · 2024 · cited 24× · PMID 39445025 · DOI 10.3389/fimmu.2024.1454747
Application of novel CAR technologies to improve treatment of autoimmune disease.
Cheever A, Kang CC, O'Neill KL, Weber KS. · · 2024 · cited 18× · PMID 39445021 · DOI 10.3389/fimmu.2024.1465191
Current advancements in cellular immunotherapy for autoimmune disease.
Berry CT, Frazee CS, Herman PJ, Chen S, et al · · 2025 · cited 15× · PMID 39821376 · DOI 10.1007/s00281-024-01034-5
Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
Lyu X, Gupta L, Tholouli E, Chinoy H. · · 2024 · cited 15× · PMID 37982747 · DOI 10.1093/rheumatology/kead616
CAR immunotherapy in autoimmune diseases: promises and challenges.
Yu J, Yang Y, Gu Z, Shi M, et al · · 2024 · cited 13× · PMID 39411714 · DOI 10.3389/fimmu.2024.1461102

Verify or expand the search:

Other trials of 4SCAR T cells

Trials testing the same drug.

NCT04430595 — Multi-4SCAR-T Therapy Targeting Breast Cancer · Phase 1, PHASE2 · unknown

Other recruiting trials for Autoimmune Diseases

Currently open trials in the same condition.

NCT06948110 — Deciphering the Genetic Architecture of Autoimmune Diseases · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07408336 — Clinical Study of AFN50 Injection in the Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting

Other Shenzhen Geno-Immune Medical Institute trials

Trials by the same sponsor.

NCT07501156 — H3K27M-specific Immune Effector Cells Targeting DMG/DIPG · Phase 1, PHASE2 · recruiting
NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
NCT07180927 — DLL3 CAR-T Therapy Targeting Brain Tumors · Phase 1, PHASE2 · recruiting
NCT07193966 — NG2 and DLL3 CAR-T Cells Targeting Melanoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05459870 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Geno-Immune Medical Institute
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05459870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing